ASH Clinical News ACN_4.5_FULL_ISSUE_DIGITAL - Page 10

The Society Pages
surprised with the cost of fertility treatments , unsure if they will go through early menopause , or unaware of their options as a whole .”
Through the project , Dr . Benedict and her team will collect data on women ’ s awareness of the fertility implications of cancer treatment , their decision-support needs , and their preferences and perceived barriers .
Source : Feinstein Institute press release , December 18 , 2017 .
Harrington Discovery Institute Announces 2018 Grant Funding
The Harrington Discovery Institute at University Hospitals in Cleveland , Ohio , announced the recipients of the 2018 Harrington Scholar-Innovator Award , which supports breakthrough research discoveries .
The recipients receive financial support ( up to $ 700,000 ) and guidance from a team of pharmaceutical industry experts through the Institute ’ s Innovation Support Center , which oversees drug discovery .
“ We hear from our scholars that the tailored guidance [ these winners ] receive throughout the program and the connection to a for-profit accelerator are vital to success ,” said Jonathan Stamler , MD , president of the Harrington Discovery Institute . “ We are pleased to see the results , which to date include launching 20 companies , assisting five programs in entering the clinic , and licensing five technologies to big pharma .”
Some of the 2018 Harrington Scholar-Innovator Award recipients include :
Suneet Agarwal , MD , PhD
David Sykes , MD , PhD
Adrian Wiestner , MD , PhD
• Suneet Agarwal , MD , PhD , Boston Children ’ s Hospital , who will study modulators of telomere diseases
• David Sykes , MD , PhD , Massachusetts General Hospital , who will develop new leukemia treatments
• Adrian Wiestner , MD , PhD , National Heart , Lung , and Blood Institute / NIH , whose work enhances the potency of antibody therapeutics for cancer
Source : Harrington Discovery Institute press release , January 18 , 2018 .
The Harry T . Mangurian Jr . Foundation Provides $ 20 Million in Funding for the Mayo Clinic
The Mayo Clinic in Fort Lauderdale , Florida , received $ 20 million from The Harry T . Mangurian Jr . Foundation to support expansion projects for the facility and build a new center for cancer and neurologic care . The building will be named the “ Dorothy J . and Harry T . Mangurian Jr . Building ” in honor of Harry T . Mangurian and his wife , Dorothy Mangurian . Harry died of leukemia in 2008 and Dorothy was diagnosed with Lewy body dementia and passed away in 2015 .
The Mayo Clinic has begun construction on this center , and it is expected to open in late summer .
Source : Mayo Clinic press release , January 23 , 2018 .
Damon Runyon Cancer Research Foundation Awards $ 3 Million to Young Scientists
The Damon Runyon Cancer Research Foundation announced the 2018 recipients of its Damon Runyon-Rachleff Innovation Award . The award provides funding for cancer research with “ high-risk / high-reward ” ideas that lack sufficient preliminary data to obtain traditional funding .
Six early-career scientists ( four individuals and one collaborative team ) received five initial twoyear grants of $ 300,000 for projects that have the potential to impact the prevention , diagnosis , and treatment of cancer .
The 2018 Damon Runyon-Rachleff Innovators working in hematologic malignancies include :
• Eric S . Fischer , PhD , of the Dana-Farber Cancer Institute in Boston
Dr . Fischer will assess the molecular understanding for the
Eric S . Fischer , PhD mechanism of action of “ degraders ” ( small molecules that hijack
the cellular waste disposal system ) and develop degraders to target oncogenic gene products for many cancers .
Arnold S . Han , MD , PhD
• Arnold S . Han , MD , PhD , of Columbia University in New York
Dr . Han will investigate a strategy to identify T cells and use genetic engineering to enable their full potential . His work investigates T-cell immunity in human colorectal cancer , and he anticipates that the findings will be applicable to other types of cancer .
• Wayne O . Miles , PhD , of The Ohio State University in Columbus
Dr . Miles aims to identify factors that block the production of cell
Wayne O . Miles , PhD death proteins and determine which prevent the death of
retinoblastoma 1 – lacking cancer cells . He hopes to learn about the mechanisms supporting cancer cell survival , as well as those preventing their death .
Each awardee can secure up to two additional years of funding ( defined as Stage 2 funding ) for a total of up to $ 600,000 over four years . This year , five awardees received Stage 2 funding :
Christin E . Burd , PhD
• Christin E . Burd , PhD , of the Ohio State University in Columbus
Dr . Burd will conduct mutation-specific studies of RAS in a variety of tumor types , including melanoma , thyroid cancer , and acute myeloid leukemia . She hopes her research will lead to a new understanding of RAS mechanism and function , resulting in better targeted therapeutics .
• Scott J . Dixon , PhD , of Stanford University in Palo Alto , California
Dr . Dixon is studying whether the altered metabolism of
Scott J . Dixon , PhD cancer cells creates new vulnerabilities that can be exploited
therapeutically . He is investigating how NRF2 balances the demand for new glutathione synthesis with the need to avoid glutathione-mediated reductive stress ( a cellular concept in which too much glutathione could lead to cell growth arrest and death ).
• Philip A . Romero , PhD , of the University of Wisconsin in Madison
Dr . Romero is developing a new technology that can be used to
Philip A . Romero , PhD detect circulating tumor cells ( CTCs ) in the bloodstream . His
approach is to develop a “ DNA-based logic circuit ” to detect and profile CTCs , which could ultimately be applied to cancer diagnosis , prognosis indication , and patient response .
Peter J . Turnbaugh , PhD
• Peter J . Turnbaugh , PhD , of the University of California , San Francisco
Dr . Turnbaugh seeks to determine how the gut microbiome contributes to drug efficacy and resistance .
• Roberto Zoncu , PhD , of the University of California , Berkeley
Dr . Zoncu will synthesize novel molecules that can specifically
Roberto Zoncu , PhD disable the lysosomalmammalian target of rapamycin
complex 1 signaling pathway to block tumor growth . He will investigate how this pathway controls the function of the lysosome and the mitochondria in mediating the resilience of cancer cells . ●
Source : Damon Runyon Cancer Research Foundation press release , January 23 , 2018 .
8 ASH Clinical News April 2018
The Society Pages surprised with the cost of fertility treatments, unsure if they will go through early menopause, or unaware of their options as a whole.” Through the project, Dr. Benedict and her team will collect data on women’s awareness of the fertility implications of cancer treatment, their decision-support needs, and their preferences and perceived barriers. Source: Feinstein Institute press release, December 18, 2017. Harrington Discovery Institute Announces 2018 Grant Funding The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, announced the re- cipients of the 2018 Harrington Scholar-Innovator Award, which supports breakthrough research discoveries. The recipients receive financial support (up to $700,000) and guidance from a team of pharma- ceutical industry experts through the Institute’s Innovation Support Center, which oversees drug discovery. “We hear from our scholars that the tailored guidance [these winners] receive throughout the program and the connection to a for-profit accelera- tor are vital to success,” said Jonathan Stamler, MD, president of the Harrington Discovery Institute. “We are pleased to see the results, which to date include launching 20 companies, assisting five programs in entering the clinic, and licensing five tech- nologies to big pharma.” Some of the 2018 Harrington Scholar-Innovator Award recipi- ents include: Suneet Agarwal, MD, PhD David Sykes, MD, PhD • Suneet Agarwal, MD, PhD, Boston Children’s Hospital, who will study modulators of telomere diseases • David Sykes, MD, PhD, Massachusetts General Hospital, who will develop new leukemia treatments • Adrian Wiestner, MD, PhD, National Heart, Lung, and Blood Institute/NIH, whose work enhances the potency of antibody therapeutics for cancer Adrian Wiestner, MD, PhD Source: Harrington Discovery Institute press release, January 18, 2018. The Harry T. Mangurian Jr. Foundation Provides $20 Million in Funding for the Mayo Clinic The Mayo Clinic in Fort Lauderdale, Florida, received $20 million from The Harry T. Mangurian Jr. Foundation to support expansion projects for the facility and build a new center for cancer and neurologic care. The building will be named the “Dorothy J. and Harry T. Mangurian Jr. Building” in honor of Harry T. Mangurian and his wife, Dorothy Mangurian. Harry died of leukemia in 2008 and Dorothy was diagnosed with Lewy body 8 ASH Clinical News dementia and passed away in 2015. The Mayo Clinic has begun construction on this center, and it is expected to open in late summer. Source: Mayo Clinic press release, January 23, 2018. Dr. Burd will conduct mutation-specific studies of RAS in a variety of tumor types, including mela- noma, thyroid cancer, and acute myeloid leuke- mia. She hopes her research will lead to a new understanding of RAS mechanism and function, resulting in better targeted therapeutics. Damon Runyon Cancer Research Foundation Awards $3 Million to Young Scientists The Damon Runyon Cancer Research Founda- tion announced the 2018 recipients of its Damon Runyon-Rachleff Innovation Award. The award provides funding for cancer research with “high-risk/ high-reward” ideas that lack sufficient prelimi- nary data to obtain traditional funding. Six early-career scientists (four individuals and one collaborative team) received five initial two- year grants of $300,000 for projects that have the potential to impact the prevention, diagnosis, and treatment of cancer. The 2018 Damon Runyon-Rachleff Innovators working in hematologic malignancies include: • Eric S. Fischer, PhD, of the Dana-Farber Cancer Institute in Boston Dr. Fischer will assess the mo- lecular understanding for the mechanism of action of “degrad- Eric S. Fischer, PhD ers” (small molecules that hijack the cellular waste disposal system) and develop degraders to target oncogenic gene products for many cancers. • Scott J. Dixon, PhD, of Stanford University in Palo Alto, California Dr. Dixon is studying whether the altered metabolism of cancer cells creates new vulner- Scott J. Dixon, PhD abilities that can be exploited therapeutically. He is investigating how NRF2 bal- ances the demand for new glutathione synthesis with the need to avoid glutathione-mediated reductive stress (a cellular concept in which too much glutathione could lead to cell growth arrest and death). • Philip A. Romero, PhD, of the University of Wisconsin in Madison Dr. Romero is developing a new technology that can be used to Philip A. Romero, PhD detect circulating tumor cells (CTCs) in the bloodstream. His approach is to develop a “DNA-based logic circuit” to detect and profile CTCs, which could ultimately be applied to cancer diagnosis, prognosis ind 6ЧFBFVB&W76R( WFW"GW&&VvB`FRVfW'6Gb6Ɩf&6g&666( &B2BB`6V&VfW'6GWp&G"vfW7FvFR7G&BЦVwFFVFgB6V2BW6PvVWF2VvVW&rFV&P&B2BFV"gVFVF2v&@fW7FvFW2B6VVGইV6&V7F66W"BRF6FW2F@FRfFw2v&RƖ6&RFFW"GW2`66W"( vR֖W2B`FR7FFRVfW'6G6V'W0G"֖W22FFVFgf7F'0FB&6FR&GV7Fb6VFVF&FV2BFWFW&֖PvR֖W2@v6&WfVBFRFVF`&WF&7F( 66r66W"6V2RW2FV&&WBFRV6627W'Fr66W"6V7W'ff2vV2F6R&WfVFrFV"FVFWFW"GW&&Vv@G"GW&&Vv6VV2FFWFW"Ц֖RrFRwWB֖7&&P6G&'WFW2FG'VrVff67@&W67F6R( &&W'F7RB`FRVfW'6Gb6Ɩf&&W&VWG"7Rv7FW6RfVV7VW2FB67V6f6ǐF6&RFRǗ66Х&&W'F7R@ƖF&vWBb&ז66W6vƖrFvF&6GV"w&wFआRvfW7FvFRrF2Fv6G&2FPgV7FbFRǗ66RBFR֗F6G&VFFrFR&W6ƖV6Rb66W"6V2)x6W&6SF'V66W"&W6V&6fVFF&W72&VV6RV'#2#V6v&FVR66V7W&RWFGvFFFV'2bgVFrFVfVB27FvR"gVFrf FFbWFCcfW fW"V'2F2V"ffRv&BЦVW2&V6VfVB7FvR"gVFs6&7FR'W&B@( 6&7FR'W&BB`FR7FFRVfW'6G6V'W0&#